People · Operator
Named in public records as an officer, director or promoter · active 2009–2022 · Biotechnology, Other Health Care, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| eyeBrain Medical, Inc. | — | Biotechnology | Series C | $126.3M | $1.2B | 2022 |
| AccuVein Inc. | — | Other Health Care | Series B | $64.0M | $53.4M | 2016 |
| Tarsa Therapeutics, Inc. | — | Biotechnology | Series B | $46.8M | $21.8M | 2009 |
| bioTheranostics, Inc. | — | Other Health Care | Series B | $20.0M | $443.1M | 2016 |
| Solx Inc | — | Biotechnology | Seed | $11.3M | $99.9M | 2010 |
| Ampla Pharmaceuticals Inc | — | Pharmaceuticals | Seed | $5.4M | $138.9M | 2010 |
| MDxHealth SA | — | Other Health Care | Series A | $5.0M | $47.7M | 2022 |
Eric Bednarski at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Eric Bednarski on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Akhilesh Pathipati | 2 | 2 |
| William Link | 1 | 11 |
| Stephen Reeders | 1 | 9 |
| David Kabakoff | 1 | 7 |
| Bosun Hau | 1 | 6 |
| Lewis Geffen | 1 | 6 |
| Steve Kirby | 1 | 6 |
| James Tananbaum | 1 | 6 |
| Charles Cohen | 1 | 6 |
| J. Andy Corley | 1 | 5 |
| Jason Fisherman | 1 | 5 |
| Martin Edwards | 1 | 5 |
| Richard Levy | 1 | 4 |
| Ashleigh Palmer | 1 | 4 |
| Kevin McArdle | 1 | 3 |
| Alejandro Sanchez | 1 | 3 |
| Ron Goldman | 1 | 3 |
| Matthew Rieke | 1 | 3 |
| Richard Kollender | 1 | 3 |
| CHRISTOPHER GABRIELI | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.